ATE538776T1 - Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren - Google Patents

Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren

Info

Publication number
ATE538776T1
ATE538776T1 AT04711116T AT04711116T ATE538776T1 AT E538776 T1 ATE538776 T1 AT E538776T1 AT 04711116 T AT04711116 T AT 04711116T AT 04711116 T AT04711116 T AT 04711116T AT E538776 T1 ATE538776 T1 AT E538776T1
Authority
AT
Austria
Prior art keywords
release
carrier
active ingredients
bioactive agent
lipophilic active
Prior art date
Application number
AT04711116T
Other languages
English (en)
Inventor
Robert Ryan
Michael Oda
Original Assignee
Childrens Hosp & Res Ct Oak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32912265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE538776(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Hosp & Res Ct Oak filed Critical Childrens Hosp & Res Ct Oak
Application granted granted Critical
Publication of ATE538776T1 publication Critical patent/ATE538776T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04711116T 2003-02-14 2004-02-13 Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren ATE538776T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44750803P 2003-02-14 2003-02-14
US50803503P 2003-10-01 2003-10-01
PCT/US2004/004295 WO2004073684A2 (en) 2003-02-14 2004-02-13 Lipophilic drug delivery vehicle and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE538776T1 true ATE538776T1 (de) 2012-01-15

Family

ID=32912265

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04711116T ATE538776T1 (de) 2003-02-14 2004-02-13 Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren

Country Status (9)

Country Link
US (4) US7824709B2 (de)
EP (2) EP1596828B1 (de)
JP (2) JP4777873B2 (de)
AT (1) ATE538776T1 (de)
AU (1) AU2004212944B2 (de)
CA (1) CA2515892C (de)
ES (1) ES2376875T3 (de)
TW (3) TW201424770A (de)
WO (1) WO2004073684A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004212944B2 (en) 2003-02-14 2008-08-21 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
AU2004283078A1 (en) * 2003-10-01 2005-05-06 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
AU2007235463B2 (en) * 2006-03-30 2012-11-22 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
EP2034904B1 (de) 2006-07-01 2015-06-03 Opus KSD, Inc. Gewebebefestigungselemente und relevante einführvorrichtungen
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
EP2092834A1 (de) * 2008-02-19 2009-08-26 Innopact B.V. Verfahren und Zusammensetzungen enthaltend Sphingolipid zur Verhinderung oder Behandlung mikrobieller Infektionen
BRPI0915093A2 (pt) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
CA2730737A1 (en) * 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
US9445975B2 (en) * 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
WO2011005916A1 (en) * 2009-07-08 2011-01-13 William Marsh Rice University Nanoparticle compositions comprising a lipid bilayer and associated methods
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
KR101132626B1 (ko) * 2009-10-12 2012-04-02 주식회사 녹십자 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법
EP2368433B1 (de) * 2010-03-24 2014-05-07 Cognis IP Management GmbH Biozidzusammensetzungen, die Glycerin(ether)phosphate umfassen
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
US8895055B2 (en) * 2011-12-21 2014-11-25 The Regents Of The University Of California Telodendrimer nanodiscs without apolipoprotein
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
ES2608857T3 (es) 2012-12-18 2017-04-17 Salipro Biotech Ag Partículas Salipro
US9232943B2 (en) 2013-01-31 2016-01-12 Opus Ksd Inc. Delivering bioabsorbable fasteners
WO2015036549A1 (en) 2013-09-13 2015-03-19 Löving Robin Antigen and method for production thereof
EP3083520A4 (de) 2013-12-20 2017-08-16 Discx Llc Neuartige nanoscheiben-clathraten und verwendungen davon
SG11201705128VA (en) * 2014-12-22 2017-07-28 Consiglio Nazionale Ricerche Products for the delivery of therapeutic/diagnostic compounds to the heart
US10596117B1 (en) * 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US12226529B2 (en) 2015-08-25 2025-02-18 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
EP3284460A1 (de) 2016-08-19 2018-02-21 Salipro Biotech AG Saposinlipoproteinpartikel und bibliotheken aus rohen membranen
CN110392583B (zh) 2016-09-15 2023-01-03 加利福尼亚大学董事会 改进的杂化的末端树枝状聚合物
WO2018064350A1 (en) * 2016-09-30 2018-04-05 Eriochem Usa, Llc Apo-e modified lipid nanoparticles for drug delivery to targeted tissues and therapeutic methods
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018181538A1 (ja) * 2017-03-31 2018-10-04 株式会社カネカ ナノディスクとその製造方法
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
WO2019010418A1 (en) * 2017-07-07 2019-01-10 Drexel University THERAPEUTIC, DIAGNOSTIC AND / OR THERANOSTIC CONSTRUCTS ACTIVATED BY VOLTAGE
US20190307892A1 (en) * 2018-04-04 2019-10-10 Eriochem Usa, Llc Targeted drug delivery and therapeutic methods using apo-e modified lipid nanoparticles
EP3833762A4 (de) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonukleotidzusammensetzungen zum targeting von ccr2 und csf1r und verwendungen davon
EP3725304A1 (de) 2019-04-15 2020-10-21 Salipro Biotech AB Herstellung von salipro-partikeln
AU2020302784A1 (en) * 2019-06-28 2022-01-20 Board Of Regents, The University Of Texas System Method of reconstituting liposomal Annamycin
CA3142510A1 (en) 2019-06-28 2020-12-30 The Board Of Regents, The University Of Texas System Preparation of preliposomal annamycin lyophilizate
DE202019003092U1 (de) * 2019-07-24 2020-01-17 Ruth-Maria Korth Test zur Bestimmung von Proteophospholipiden und FIDA-Formeln zur Bestimmung von Schutzfaktoren , die mit Substraten auszugleichen sind
CN115427064A (zh) 2020-04-16 2022-12-02 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗急性病况的方法
EP4221686A2 (de) 2020-10-01 2023-08-09 Abionyx Pharma SA Zusammensetzungen mit lipidbindenden komplexen auf proteinbasis zur verwendung zur behandlung von augenerkrankungen
WO2022147471A1 (en) * 2020-12-30 2022-07-07 Lipotope, Llc Protein stabilized liposomes (psl) and methods of making thereof
JP2024514154A (ja) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3247588A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa METHODS FOR TREATING LEUKOCYTOSIS, ENDOTHELIAL DYSFUNCTION AND CARDITIS USING LIPID-BINDING PROTEIN COMPLEXES
AU2023284357A1 (en) 2022-06-10 2025-01-23 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
KR102540330B1 (ko) * 2022-10-19 2023-06-05 엠브릭스 주식회사 인지질인 포스파티딜에탄올아민을 포함하는 나노디스크
WO2024137592A1 (en) * 2022-12-19 2024-06-27 Beckman Coulter, Inc. Lipid based nanoparticle characterization
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4970144A (en) * 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
FR2609399A1 (fr) * 1987-01-13 1988-07-15 Ire Celltarg Sa Procede d'incorporation d'un ou plusieurs principes actifs lipophiles dans des lipoproteines, lipoproteines obtenues et composition pharmaceutique les contenant
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5128318A (en) † 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
DE3854940T2 (de) † 1987-05-20 1996-07-11 Rogosin Inst Rekonstituierte hdl-teilchen und ihre verwendung
US5948441A (en) 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
FR2664500B1 (fr) * 1990-07-13 1994-10-28 Lille Ii Universite Droit Sant Procede de preparation d'une lipoproteine modifiee par incorporation d'une substance active lipophile, lipoproteine modifiee ainsi obtenue et composition pharmaceutique ou cosmetique la contenant.
US5874549A (en) * 1990-09-28 1999-02-23 Neorx Corporation Acid-cleavable compound
AU9088891A (en) * 1990-11-29 1992-06-25 John E. Carbaugh Diagnostic and therapeutic compositions and methods for lipoprotein(a)
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5840707A (en) * 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
US7011827B2 (en) * 1993-11-09 2006-03-14 Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
US5652339A (en) 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
EP0752005B1 (de) * 1994-03-23 2008-10-08 Ohio University Kompaktnukleinsäure und ihre verabreichung in zellen
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US5817789A (en) * 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US20020022053A1 (en) * 1995-10-11 2002-02-21 Williams Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis, and pharmaceutical compositions and kit related thereto
MXPA98002791A (es) * 1995-10-11 2004-09-07 Esperion Luv Dev Inc Composiciones liposomales y metodos para usarlas.
CA2252617A1 (en) * 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6071493A (en) * 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
DE19640092A1 (de) * 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
US20020051813A1 (en) * 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
US6328988B1 (en) * 1999-04-23 2001-12-11 Rutgers, The State University Of New Jersey Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
US20010031262A1 (en) * 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
US20010028895A1 (en) * 2000-02-04 2001-10-11 Bisgaier Charles L. Methods of treating alzheimer's disease
US6514523B1 (en) * 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
AU2000265051A1 (en) 2000-02-18 2001-08-27 Dabur Research Foundation Vasoactive intestinal peptide analogs
AU2001257903A1 (en) * 2000-03-22 2001-10-03 The General Hospital Corporation Method for treatment of neurodegenerative diseases
AU4871001A (en) * 2000-03-24 2001-10-03 Biomira Inc Lipopeptide adjuvants
US6696081B2 (en) * 2000-06-09 2004-02-24 Duke University Carbohydrate based lipid compositions and supramolecular structures comprising same
DE10036694A1 (de) 2000-07-27 2002-02-14 Wacker Chemie Gmbh Verfahren zur Behandlung von organischen Fasern mit aminofunktionellen Organosiliciumverbindungen
EP1315971A2 (de) * 2000-07-31 2003-06-04 The Regents of The University of California Modell für alzheimer und neurodegenerative krankheiten
JP4344136B2 (ja) * 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
US7083958B2 (en) * 2000-11-20 2006-08-01 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
CA2429473C (en) 2000-11-20 2011-02-15 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
CN101284136A (zh) * 2002-12-03 2008-10-15 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
AU2004212944B2 (en) * 2003-02-14 2008-08-21 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
AU2004283078A1 (en) 2003-10-01 2005-05-06 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
EP1718282A4 (de) 2004-01-15 2010-07-14 Sinai School Medicine Verfahren und zusammensetzungen für die bilddarstellung
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof

Also Published As

Publication number Publication date
US20040229794A1 (en) 2004-11-18
TW201424770A (zh) 2014-07-01
CA2515892C (en) 2012-10-23
EP2314285B2 (de) 2019-09-18
US20100311595A1 (en) 2010-12-09
EP1596828A2 (de) 2005-11-23
EP2314285B1 (de) 2016-08-03
US20120309628A1 (en) 2012-12-06
US8268357B2 (en) 2012-09-18
WO2004073684A2 (en) 2004-09-02
TW201106988A (en) 2011-03-01
JP2007063291A (ja) 2007-03-15
WO2004073684A3 (en) 2004-11-11
US20140308339A1 (en) 2014-10-16
ES2376875T3 (es) 2012-03-20
US8821939B2 (en) 2014-09-02
TW200509986A (en) 2005-03-16
AU2004212944B2 (en) 2008-08-21
JP4777873B2 (ja) 2011-09-21
TWI433693B (zh) 2014-04-11
TWI369997B (en) 2012-08-11
CA2515892A1 (en) 2004-09-02
AU2004212944A1 (en) 2004-09-02
US7824709B2 (en) 2010-11-02
JP2006517972A (ja) 2006-08-03
EP1596828B1 (de) 2011-12-28
US9107826B2 (en) 2015-08-18
EP2314285A1 (de) 2011-04-27

Similar Documents

Publication Publication Date Title
ATE538776T1 (de) Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren
WO2005039534A8 (en) Lipophilic drug delivery vehicle and methods of use thereof
ATE374603T1 (de) Amphiphile lipid-nanopartikel zur peptid- und/oder proteininkorporation
WO2005072710A3 (en) Drugs and gene carrier particles that rapidly move through mucous barriers
EP1015008A4 (de) Verbindungen und zusammensetzungen zur administration aktiver stoffe
ATE328573T1 (de) Behandlung und zusammensetzungen zur erzielung eines hautalterungsschutzes durch corneum protease aktivatoren
DE69942680D1 (de) Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie
ITMI20031165A0 (it) Dispositivo per l'emanazione di sostanze volatili in particolare deodoranti per abitacoli di veicoli
WO2005120393A3 (en) Implantable device for drug delivery and improved visibility
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EP1303299A4 (de) Zusammensetzungen und methoden zur verstärkung der immunogenität von antigenen
WO2004063342A3 (en) Cellular delivery and activation polypeptide-nucleic acid complexes
ATE551100T1 (de) Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen
HUP0303621A3 (en) Pharmaceutical compositions containing combinations comprising an antidiarrheal agent and epothilone or an epothilone
WO2008011272A3 (en) Liquid monophasic lipid-soluble antioxidant compositions and processes for making the compositions
ATE362925T1 (de) Zusammensetungen und verfahren zur modulation von apoptose in cellen, die proteine der bc1-2- familie exprimieren
UA88300C2 (ru) Гидрогелевые композиции, которые содержат интерферон
DE60203929D1 (de) Behandlungsverfahren und pharmazeutische zusammensetzung zur notfall-empfängnisverhütung
EP1853110A4 (de) Verfahren zur bereitstellung von verfügbarem zellmaterial aus peripherblut und zusammensetzung daraus
IL158691A0 (en) Solid orally-dispersible pharmaceutical formulation
WO2005020965A3 (en) Skeletally targeted nanoparticles
IL194775A (en) Medicinal products containing anti-secretory protein for use in the treatment of dysfunction of floating fat rafts and / or kowala and / or its prevention
SG118275A1 (en) Polymers for the delivery of bioactive agents and methods of their preparation
DE602004019317D1 (de) Zubereitungen zur parenteralen Anwendung und verlängerte Freisetzung von Wirkstoffen
HUP0600778A2 (en) Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus